All glycoprotein hormones are heterodimers composed of an identical a subunit and a distinct beta subunit. Synthesis of chorionic gonadotropin (CG) occurs only in placenta of primates and horses, whereas synthesis of the other glycoprotein hormones is restricted to the pituitary in all other mammals. Consequently, in primates and horses, the alpha subunit gene must be expressed in two locations-- pituitary and placenta. Placental-specific expression of the human a subunit gene requires at least two DNA sequence elements. One confers responsiveness to cAMP (CRE), whereas the other (URE) acts in conjunction with the CRE to specify expression in the placenta. It is unclear, however, whether additional elements are required for placental-specific expression and whether any of these elements mediate the action of sex steroids or hypothalamic-releasing hormones. It is also unknown whether different combinations of cis-acting elements are required for pituitary-specific expression of the a subunit gene. To address these questions, we propose three specific aims. First, we will determine whether additional cis-acting elements are required for placental-specific expression and then characterize the molecular mechanisms underlying the interaction between the CRE and URE and any newly detected cis-acting element. The former will involve analysis of a series CAT vectors linked to alpha subunit promoter-regulatory regions containing 10 bp transversions between positions -170 and +44. Interactions between the factors that bind to cis-acting regulatory sequences will bc evaluated by using a gel-shift assay to construct saturation isotherms. Analysis by the methods of Scatchard and Hill should indicate whether these interactions involve homotropic or heterotropic cooperativity. In the second aim, transgenic mice expressing chimeric human and bovine alpha subunit genes will be used to detect cis-acting sequences required for pituitary-specific expression and to determine whether these or other cis-acting elements are required for regulation by sex-steroids or hypothalamic-releasing hormones. The goal of the third aim is to establish a pituitary-specific in vitro transcription assay and identify, characterize, and clone the trans-acting factor required for pituitary-specific expression of the alpha subunit gene.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK028559-13
Application #
3228905
Study Section
Endocrinology Study Section (END)
Project Start
1980-09-01
Project End
1994-08-31
Budget Start
1993-09-01
Budget End
1994-08-31
Support Year
13
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Salisbury, Travis B; Binder, April K; Grammer, Jean C et al. (2007) Maximal activity of the luteinizing hormone beta-subunit gene requires beta-catenin. Mol Endocrinol 21:963-71
Jorgensen, Joan S; Quirk, Christine C; Nilson, John H (2004) Multiple and overlapping combinatorial codes orchestrate hormonal responsiveness and dictate cell-specific expression of the genes encoding luteinizing hormone. Endocr Rev 25:521-42
Quirk, Christine C; Seachrist, Darcie D; Nilson, John H (2003) Embryonic expression of the luteinizing hormone beta gene appears to be coupled to the transient appearance of p8, a high mobility group-related transcription factor. J Biol Chem 278:1680-5
Mohammad, Helai P; Abbud, Rula A; Parlow, Al F et al. (2003) Targeted overexpression of luteinizing hormone causes ovary-dependent functional adenomas restricted to cells of the Pit-1 lineage. Endocrinology 144:4626-36
Jorgensen, J S; Nilson, J H (2001) AR suppresses transcription of the LHbeta subunit by interacting with steroidogenic factor-1. Mol Endocrinol 15:1505-16
Jorgensen, J S; Nilson, J H (2001) AR suppresses transcription of the alpha glycoprotein hormone subunit gene through protein-protein interactions with cJun and activation transcription factor 2. Mol Endocrinol 15:1496-504
Quirk, C C; Lozada, K L; Keri, R A et al. (2001) A single Pitx1 binding site is essential for activity of the LHbeta promoter in transgenic mice. Mol Endocrinol 15:734-46
Keri, R A; Bachmann, D J; Behrooz, A et al. (2000) An NF-Y binding site is important for basal, but not gonadotropin-releasing hormone-stimulated, expression of the luteinizing hormone beta subunit gene. J Biol Chem 275:13082-8
Abbud, R A; Ameduri, R K; Rao, J S et al. (1999) Chronic hypersecretion of luteinizing hormone in transgenic mice selectively alters responsiveness of the alpha-subunit gene to gonadotropin-releasing hormone and estrogens. Mol Endocrinol 13:1449-59
Risma, K A; Hirshfield, A N; Nilson, J H (1997) Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology 138:3540-7

Showing the most recent 10 out of 24 publications